Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Isis Pharmaceuticals

Share:
Related ISIS
Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease
AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

In a report published Monday, BMO Capital Markets reiterated its Outperform rating on Isis Pharmaceuticals (NASDAQ: ISIS) and raised its price target from $12.00 to $17.00.

BMO Capital Markets noted, “We are reiterating our Outperform rating on shares of ISIS and increasing our price target to $17 following our meeting with management. With the near-term focus on the KYNAMRO PDUFA, we are increasingly confident in approval and believe that upside potential extends beyond the initial commercial opportunity and to validation of an emerging late-stage pipeline. Relative to the value of KYNAMRO in HoFH, estimated at an NPV of $3/share, we believe that pipeline value is considerably greater, with an estimated NPV of $14/share, primarily driven by only 1 of 25 programs in the ASO for ApoCIII for triglycerides.”

Isis Pharmaceuticals closed on Friday at $13.28.

Latest Ratings for ISIS

DateFirmActionFromTo
Jun 2015NeedhamReiteratesBuy
Jun 2015JP MorganMaintainsNeutral
Mar 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (ISIS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters